{"id":390815,"date":"2017-12-07T00:00:00","date_gmt":"2017-12-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0004-2017-biopharma-chronic-obstructive-pulmonary-disease-access-and-reimbursement-us-2017\/"},"modified":"2026-04-15T09:57:15","modified_gmt":"2026-04-15T09:57:15","slug":"acreim0004-2017-biopharma-chronic-obstructive-pulmonary-disease-access-and-reimbursement-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0004-2017-biopharma-chronic-obstructive-pulmonary-disease-access-and-reimbursement-us-2017\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | Access and Reimbursement | US | 2017"},"content":{"rendered":"<p>Current market-leading therapies in the U.S. COPD market will face challenges from emerging drugs, especially generic versions of Spiriva, Symbicort, and Advair. Surveyed physicians often report\u00a0that familiarity is a key driver of drug selection within a class, but clinical factors are significant both for physicians and MCOs. Cost-control measures are critical for MCOs, and have a moderate impact on prescribing decisions.<\/p>\n<p>Pharmacoeconomic data are anticipated to be of increasing importance, especially with the launch of additional therapies within the LABA\/LAMA class and the new LABA\/LAMA\/ICS FDC class.<\/p>\n","protected":false},"template":"","class_list":["post-390815","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390815\/revisions"}],"predecessor-version":[{"id":393939,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390815\/revisions\/393939"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}